Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition

Inclusion Criteria: 1. Healthy volunteers, men and women aged 18 to 45 years (inclusive); 2. Provided written Informed Consent Form of a Healthy Volunteer for Participation in the Clinical Study before the beginning of any screening procedures; 3. Ability (to the opinion of the investigator) to fulfill all requirements of the Study Protocol, i.e. the volunteer's ability for adequate collaboration; 4. Body mass index is within the limits (\> 18,5 kg/m2 and \< 30,0 kg/m2); 5. Persons free from any acute and chronic diseases of cardiovascular system, neuroendocrine system, kidneys, liver, gastrointestinal tract, and respiratory system; 6. Results of physical, instrumental, and laboratory examination of volunteers are within the normal limits, or any deviations are classified by the investigator as clinically irrelevant; 7. Chest fluorography or radiography results are within the normal limits (the examination should be carried out no earlier than 9 months before the screening moment), or any deviation is classified by the investigator as clinically irrelevant; 8. Women and men have to use medically confirmed barrier method of contraception during the whole study period; 9. Volunteers have to be non-smokers or smoke up to 10 cigarettes a day inclusive; 10. Volunteers need to undertake to follow all general diet limitations during the whole study period. Exclusion Criteria: 1. Subjects with evidence or suspicion of any relevant clinical abnormality (as based on medical history, physical examination, vital signs, chest X-ray, and 12-lead ECG) 2. Known hypersensitivity to meloxicam and/or other investigational products ingredients; 3. Compromised allergologic history; 4. Subjects who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs; 5. Active peptic ulcer, gastrointestinal perforation or bleeding within the last 6 months; 6. Subjects with peripheral oedema; 7. Any previously incurred diseases or surgical interventions which, to the investigator's opinion, may affect pharmacokinetics of the investigational product; 8. Positive result of HIV, syphilis, hepatitis B and C markets test; 9. Positive result of urine test for narcotic substances (amphetamine, metamphetamine, morphine, marijuana, cocaine); 10. Positive result of alcohol vapors test in expired air; 11. Pregnancy (positive result of urine pregnancy test in women) and lactation period; 12. Incurred acute infectious diseases within 28 days before beginning of the study; 13. Use of any medicinal products within 14 days before beginning of the study; 14. Blood donation or blood loss of more than 300 ml in less than 30 days before beginning of the study; 15. Participation in any other clinical study during the last 90 days before beginning of the study; 16. Other reasons which, to the investigator's opinion, make the volunteer's participation in the study undesirable.